Sequential neurohumoral measurements in patients with congestive heart failure

https://doi.org/10.1016/0002-8703(88)90729-6Get rights and content

Abstract

Patients with chronic congestive heart failure are known to have increased plasma norepinephrine and plasma renin activity. In order to evaluate neurohumoral changes over time, we measured plasma norepinephrine and plasma renin activity at baseline and sequentially during follow-up in 49 patients with chronic, stable congestive heart failure. All patients were treated with digitalis and diuretics. Converting enzyme inhibitor therapy was prescribed as adjunctive therapy in 22 patients, while 10 patients were taking hydralazine and/or isosorbide dinitrate, seven were taking prazosin, and 10 had no adjunctive therapy. Patients were divided into those taking converting enzyme inhibitors (group I, n = 22) and those not taking converting enzyme inhibitors (group II, n = 27). Group I was followed for a median (25th to 75th percentiles) of 24.3 (18 to 27.9) months, while group II was followed for 18.7 (11.9 to 36.5) months. Results indicate that patients in group I demonstrate a significant positive trend for rise in plasma norepinephrine of 11.7 pg/ml per month (7.8 to 15 pg/ml per month, 95% confidence interval). Patients in group II also demonstrated a significant positive trend in plasma norepinephrine over time of 6.6 pg/ml per month (2.2 to 11.1 pg/ml per month). Moreover, there was a progressive trend upward in plasma renin activity over time in group II (median 0.34 ng/ml/hr per month; range 0.13 to 0.54). The data indicate that there is a significant trend of neurohumoral activation over time in patients with chronic, clinically stable congestive heart failure. The increase in plasma norepinephrine does not appear to be prevented by chronic converting enzyme inhibitor therapy, although these data cannot rule out the possibility of a reduced slope compared to a control group.

References (33)

  • G.S Francis et al.

    The neurohumoral axis in congestive heart failure

    Ann Intern Med

    (1984)
  • JN Cohn et al.

    Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

    N Engl J Med

    (1984)
  • TB Levine et al.

    Effects of orthotopic heart transplantation on sympathetic control mechanisms in congestive heart failure

    Am J Cardiol

    (1986)
  • GS Francis

    Plasma catecholamines in patients with congestive heart failure

    Cardiovasc Rev Rep

    (1985)
  • VJ Dzau et al.

    Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure

    Circulation

    (1981)
  • BG Zimmerman et al.

    Pattern of renal vasoconstriction and transmitter release during sympathetic stimulation in the presence of angiotensin and cocaine

    J Pharmacol Exp Ther

    (1968)
  • Cited by (58)

    • Atrial ganglionated plexi stimulation may be an effective therapeutic tool for the treatment of heart failure

      2013, Medical Hypotheses
      Citation Excerpt :

      It has been shown in the past decades that neurohumoral activation plays an important role in the pathophysiology of heart failure. The autonomic sympathetic/parasympathetic imbalance, i.e. the activation of sympathetic nervous system and the reduction of parasympathetic activity, constitutes a fundamental element of chronic heart failure pathophysiology [4–7]. It has been shown that the autonomic imbalance is associated with progressive ventricular remodeling, ventricular arrhythmia generation and disease progression [8].

    • Impact of angiotensin II on skeletal muscle metabolism and function in mice: Contribution of IGF-1, Sirtuin-1 and PGC-1α

      2013, Acta Histochemica
      Citation Excerpt :

      Activation of the renin–angiotensin–aldosterone system occurs in the context of both normal cardiovascular aging and numerous cardiovascular diseases, including hypertension and chronic heart failure (CHF). Significant increased concentrations of angiotensin II (Ang-II) in the plasma could be detected in particular in patients with CHF (Cohn et al., 1984; Francis et al., 1988). Another hallmark of patients with CHF is a reduced exercise tolerance accompanied by impaired skeletal muscle function, including impaired contractility (Perreault et al., 1993), enhanced immune activation (Toth et al., 2006), reduced muscle protein synthesis (Toth et al., 2005), and enhanced muscle protein degradation (Tisdale, 2002).

    View all citing articles on Scopus

    Supported by Grants HL 22977, HL 07184, HL 32427, and RR-400 from the National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, Md., and by a Merit Review Grant from the Research Service, Veterans Administration, Washington, D.C.

    View full text